AVBP

B. Riley Securities Coverage: B. Riley Securities has initiated coverage on ArriVent Biopharma, highlighting its lead drug candidate firmonertinib, which is being studied for treating non-small cell lung cancer (NSCLC) with specific mutations. The analyst estimates a potential market of ~$700 million/year and has given the stock a Buy rating with a price target of $37.

Clinical Trials and Market Position: Firmonertinib shows promising results in clinical trials, particularly for patients with EGFR exon 20 insertion and PACC mutations, positioning it favorably against existing treatments. The company ended 2024 with $266.5 million in cash and its stock rose by 0.56% to $19.71.

Analyst Ratings Updates: Several Wall Street analysts have initiated coverage on various companies, including ArriVent BioPharma with a Buy rating and a price target of $37, Amentum Holdings with a Neutral rating and a target of $21, and Celldex Therapeutics with an Overweight rating and a target of $46.

Microsoft Coverage Initiation: Scotiabank analyst Patrick Colville has given Microsoft Corporation a Sector Outperform rating with a price target of $470, while the stock closed at $387.82 on Wednesday.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Top Upgrades and Downgrades: Notable upgrades include Jefferies raising Airbnb to Buy, while downgrades feature Sherwin-Williams being lowered to Hold by Jefferies. Other significant changes involve Shift4 Payments and DocuSign receiving positive adjustments, while Emerson and Occidental Petroleum faced downgrades due to market conditions.

New Initiations: Mizuho initiated coverage of SanDisk with an Outperform rating, citing improving industry fundamentals, while TD Cowen began coverage of SailPoint, highlighting its potential in a large market. Other companies like Super Micro and Karman also received favorable ratings from various firms, indicating strong growth prospects.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Logility Acquisition Announcement: Shares of Logility Supply Chain Solutions surged 23.2% in pre-market trading following Aptean's announcement of a $14.30-per-share all-cash acquisition deal.

Market Movements: Several stocks experienced significant pre-market gains, including HWH International (up 80.5%) and Tevogen Bio Holdings (up 65.2%), while others like MiMedx Group saw substantial declines (down 42%).

Exclusive License Agreement: ArriVent Biopharma has entered into an exclusive global license agreement with Lepu Biopharma for the development and commercialization of MRG007, a novel antibody-drug conjugate targeting gastrointestinal cancers, excluding Greater China.

Financial Details and Future Plans: The agreement includes $47 million in upfront and milestone payments, with potential additional payments up to $1.16 billion; the first Investigational New Drug submission is planned for 2025, focusing on colorectal and pancreatic cancers.

Exclusive License Agreement: ArriVent BioPharma has secured an exclusive license from Lepu Biopharma for MRG007, an antibody-drug conjugate aimed at treating gastrointestinal cancers, granting them global rights outside Greater China.

Financial Terms: The agreement includes a $47M upfront payment and potential additional earnings of up to $1.16B in milestone payments and royalties, while maintaining ArriVent's projected cash runway into 2026.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Positive Clinical Data: ArriVent BioPharma Inc. announced promising interim results from a Phase 1b trial for firmonertinib, showing it as a well-tolerated and effective treatment for non-small cell lung cancer (NSCLC) patients with EGFR PACC mutations.

Therapeutic Potential: The drug demonstrated dose-dependent activity and CNS antitumor effects, suggesting its potential as a chemotherapy-free option for various EGFR mutation types in NSCLC therapy.

Analyst Ratings: Sam Slutsky of LifeSci Capital maintains a Buy rating on ArriVent BioPharma, Inc. with a price target of $33.00, citing the potential efficacy of firmonertinib in treating non-small cell lung cancer (NSCLC) patients with EGFR PACC mutations.

Company Overview: ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers, particularly NSCLC, and is currently advancing firmonertinib through clinical trials.

Trend Investing Insights: Successful short-term investing relies on timing entries into trends, confirming sustainability through strong fundamentals and positive earnings revisions to avoid potential losses from trend reversals.

Stock Highlight - ArriVent BioPharma (AVBP): AVBP shows a solid price increase of 26.6% over 12 weeks and is trading at 86.3% of its 52-week range, with a Zacks Rank #2 (Buy) indicating strong potential for continued upward momentum.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and real-time intelligence to help traders succeed in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate market insights.

Earnings Report: ArriVent BioPharma reported a second-quarter 2024 earnings per share of -65 cents, missing the analyst estimate of -54 cents, and did not report any revenue for the quarter.

Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate quarterly earnings report coverage, providing quick insights on key financial figures without human intervention.

Presentation of Firmonertinib Data: ArriVent BioPharma will present interim data from a Phase 1b study on firmonertinib, an EGFR inhibitor for non-small cell lung cancer (NSCLC) with PACC mutations, at the 2024 World Conference on Lung Cancer in San Diego, along with hosting a related virtual webinar.

About Firmonertinib: Firmonertinib is an oral medication approved in China for certain NSCLC patients and has received FDA Breakthrough Therapy and Orphan Drug designations for treating specific EGFR mutation types, highlighting its potential in addressing unmet medical needs in lung cancer therapy.